<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04736628</url>
  </required_header>
  <id_info>
    <org_study_id>1366-0022</org_study_id>
    <secondary_id>2020-002930-33</secondary_id>
    <nct_id>NCT04736628</nct_id>
  </id_info>
  <brief_title>A Study to Test the Effect of Different Doses of BI 685509 on Kidney Function in People With Chronic Kidney Disease Who do Not Have Diabetes</brief_title>
  <official_title>Randomised, Double-blind (Within Dose Groups), Placebo Controlled and Parallel Group Trial to Investigate the Effects of Different Doses of Oral BI 685509 Given Over 20 Weeks on UACR Reduction in Patients With Non-diabetic Kidney Disease.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Boehringer Ingelheim</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Boehringer Ingelheim</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is open to adults who have kidney disease and do not have diabetes. The purpose of&#xD;
      the study is to find out whether a medicine called BI 685509 improves kidney function. Three&#xD;
      different doses of BI 685509 are tested in this study.&#xD;
&#xD;
      Participants get either one of the three doses of BI 685509 or placebo. It is decided by&#xD;
      chance who gets which BI 685509 dose and who gets placebo. Participants take BI 685509 or&#xD;
      placebo as tablets 3 times a day. Placebo tablets look like BI 685509 tablets but do not&#xD;
      contain any medicine. Participants continue taking their usual medicine for kidney disease&#xD;
      throughout the study.&#xD;
&#xD;
      Participants are in the study for about 7 months. During this time, they visit the study site&#xD;
      about 11 times. Where possible, about 6 of the 11 visits can be done at the participant's&#xD;
      home instead of the study site. The trial staff may also contact the participants by phone or&#xD;
      video call.&#xD;
&#xD;
      Kidney function is assessed based on the analysis of urine samples, which participants&#xD;
      collect at home. At the end of the trial the results are compared between the different doses&#xD;
      of BI 685509 and placebo. During the study, the doctors also regularly check the general&#xD;
      health of the participants.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">April 27, 2021</start_date>
  <completion_date type="Anticipated">August 16, 2022</completion_date>
  <primary_completion_date type="Anticipated">July 19, 2022</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Change from baseline in log transformed Urine Albumin Creatinine Ratio (UACR) measured in 10-hour urine after 20 weeks of trial treatment.</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>Change from baseline in log transformed UACR measured in First Morning Void urine after 20 weeks of trial treatment.</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving UACR decreases in 10-hour urine of at least 20% from baseline after 20 weeks of trial treatment.</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Proportion of patients achieving UACR decreases in First Morning Void urine of at least 20% from baseline after 20 weeks of trial treatment.</measure>
    <time_frame>Up to 20 weeks</time_frame>
  </secondary_outcome>
  <number_of_arms>6</number_of_arms>
  <enrollment type="Anticipated">240</enrollment>
  <condition>Chronic Kidney Disease</condition>
  <arm_group>
    <arm_group_label>Dose group 1: BI 685509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 1: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for low dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2: BI 685509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose followed by up-titration to medium dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 2: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for low dose followed by up-titration to medium dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3: BI 685509</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Low dose followed by up-titration to medium dose, followed by up-titration to high-dose.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Dose group 3: Matching placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Matching placebo for low dose followed by up-titration to medium dose, followed by up-titration to high dose.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>BI 685509</intervention_name>
    <description>BI 685509</description>
    <arm_group_label>Dose group 1: BI 685509</arm_group_label>
    <arm_group_label>Dose group 2: BI 685509</arm_group_label>
    <arm_group_label>Dose group 3: BI 685509</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Placebo</intervention_name>
    <description>Placebo</description>
    <arm_group_label>Dose group 1: Matching placebo</arm_group_label>
    <arm_group_label>Dose group 2: Matching placebo</arm_group_label>
    <arm_group_label>Dose group 3: Matching placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Signed and dated written informed consent in accordance with International Council on&#xD;
             Harmonisation-Good Clinical Practice (ICH-GCP) and local legislation prior to&#xD;
             admission to the trial&#xD;
&#xD;
          -  Male or female patients aged = 18 years at time of consent&#xD;
&#xD;
          -  Estimated glomerular filtration rate (eGFR) (Chronic Kidney Disease Epidemiology&#xD;
             Collaboration [CKD-EPI] formula) ≥ 20 and &lt; 90 mL/min/1.73 m2 at Visit 1 by central&#xD;
             laboratory analysis. eGFR must remain ≥20 mL/min/1.73 m2 after Visit 1 up to the start&#xD;
             of Visit 3, measured by central or any local laboratory analysis&#xD;
&#xD;
          -  Urine albumin creatinine ratio (UACR) ≥ 200 and &lt; 3,500 mg/g in spot urine (midstream&#xD;
             urine sample) by central laboratory analysis at Visit 1&#xD;
&#xD;
          -  Patients with macroalbuminuria (&gt;300 mg/g) should be treated with the highest&#xD;
             tolerated dose of either Angiotensin Converting Enzyme inhibitor (ACEi) or Angiotensin&#xD;
             Receptor Blocker (ARB) (but not both). For patients with microalbuminuria the use of&#xD;
             ACEi or ARB is at the discretion of the Investigator. Treatment should be at a stable&#xD;
             dose for ≥ 4 weeks before Visit 1 with no planned change of the therapy during the&#xD;
             trial.&#xD;
&#xD;
          -  If the patient is taking any of the following medications they should be on a stable&#xD;
             dose at least 4 weeks prior to visit 1 until start of treatment, with no planned&#xD;
             change of the therapy during the trial: anti-hypertensives, NSAIDs, endothelin&#xD;
             receptor antagonists, systemic steroids or SGLT2 inhibitors&#xD;
&#xD;
          -  Diagnosis of Chronic Kidney Disease (CKD) as defined by Kidney Disease: Improving&#xD;
             Global Outcomes (KDIGO) definition&#xD;
&#xD;
          -  In the Investigator's opinion:&#xD;
&#xD;
               -  Hypertensive kidney disease OR&#xD;
&#xD;
               -  Chronic glomerulonephritis defined as one of the following:&#xD;
&#xD;
                    -  Immunoglobulin A (IgA) nephropathy&#xD;
&#xD;
                    -  Membranous nephropathy&#xD;
&#xD;
                    -  Focal Segmental Glomerulosclerosis (FSGS) Further inclusion criteria apply&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Treatment with Renin Angiotensin Aldosterone System (RAAS) interventions (apart from&#xD;
             either ACEi or ARB), phosphodiesterase inhibitors, nitrates, soluble Guanylate Cyclase&#xD;
             (sGC)-stimulators/activators(other than trial treatment) or any other restricted&#xD;
             medication (including Organic Anion-Transporting Polypeptide 1B1 and 1B3 (OATP1B1/3)&#xD;
             inhibitors, Uridine 5'-diphosphate -glucuronosyltransferase (UGT) inhibitors/inducers)&#xD;
             as provided in the Investigator Site File (ISF) within 4 weeks prior to visit 1 and&#xD;
             throughout screening and baseline run-in. Patients who must or wish to continue the&#xD;
             intake of restricted medications or any drug considered likely to interfere with the&#xD;
             safe conduct of the trial&#xD;
&#xD;
          -  Any clinically relevant laboratory value from screening until start of trial treatment&#xD;
             which, in the investigator's judgement, puts the patient at additional risk&#xD;
&#xD;
          -  Diagnosed with diabetes mellitus according to local guidelines&#xD;
&#xD;
          -  Any immunosuppression therapy or immunotherapy in last 3 months prior to visit 1 and&#xD;
             throughout screening and baseline run-in (except prednisolone ≤10 mg or equivalent)&#xD;
&#xD;
          -  Acute kidney injury (AKI) according to the Kidney Disease: Improving Global Outcomes&#xD;
             (KDIGO) definition in the 30 days prior to Visit 1 until the start of trial treatment&#xD;
&#xD;
          -  Planned start of chronic renal replacement therapy during the trial or end stage renal&#xD;
             disease before start of trial treatment&#xD;
&#xD;
          -  Known history of moderate or severe symptomatic orthostatic dysregulation as judged by&#xD;
             the investigator before start of trial treatment&#xD;
&#xD;
          -  The patient has an active infection with Severe Acute Respiratory Syndrome Coronavirus&#xD;
             2 (SARS-CoV-2) (or is known to have a positive test from screening until&#xD;
             randomisation)&#xD;
&#xD;
          -  Further exclusion criteria apply&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Boehringer Ingelheim</last_name>
    <phone>1-800-243-0127</phone>
    <email>clintriage.rdg@boehringer-ingelheim.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Riverside Nephrology Physicians</name>
      <address>
        <city>Riverside</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mohammed Khan</last_name>
      <phone>+001(800)797-1695</phone>
      <email>mkhan@nariresearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidney and Hypertension Center</name>
      <address>
        <city>Victorville</city>
        <state>California</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Edgard Vera Tapia</last_name>
      <phone>+001(760)245-2760</phone>
      <email>edgardvera@msn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Middlebury</city>
        <state>Connecticut</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sina Raissi</last_name>
      <phone>+001(203)758-1800</phone>
      <email>sinaraissi@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chase Medical Research, LLC</name>
      <address>
        <city>Waterbury</city>
        <state>Connecticut</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Joseph Soufer</last_name>
      <phone>+001(203)419-4420</phone>
      <email>jsoufer@chasemr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nephrology Associates, P.A.</name>
      <address>
        <city>Newark</city>
        <state>Delaware</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Theodore Saad</last_name>
      <phone>+001(302)225-0451</phone>
      <email>tsaad@delawarekidney.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Indago Research and Health Center</name>
      <address>
        <city>Hialeah</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Cardona</last_name>
      <phone>+001(305)825-6588</phone>
      <email>jcardona@indagoresearch.org</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Panax Clinical Research</name>
      <address>
        <city>Miami Lakes</city>
        <state>Florida</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Robert Perry</last_name>
      <phone>+001(305)698-4500</phone>
      <email>rperry@panaxcr.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>Columbus</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vinayak Ramanath</last_name>
      <phone>+001(706)593-2127</phone>
      <email>vramanath79@googlemail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research, LLC</name>
      <address>
        <city>Savannah</city>
        <state>Georgia</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Bradley</last_name>
      <phone>+001(912)443-4253</phone>
      <email>pbradley@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Boise Kidney and Hypertension PLLC</name>
      <address>
        <city>Nampa</city>
        <state>Idaho</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arnold Silva</last_name>
      <phone>+001(208)615-4395</phone>
      <email>asilva@boisekidney.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Research by Design, LLC</name>
      <address>
        <city>Chicago</city>
        <state>Illinois</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Paul Crawford</last_name>
      <phone>+001(708)952-3040</phone>
      <email>pcrawford@researchbd.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renal Associates of Baton Rouge</name>
      <address>
        <city>Baton Rouge</city>
        <state>Louisiana</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Michael Roppolo</last_name>
      <phone>+001(225)767-4893</phone>
      <email>mroppolo@renalassociates.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Louisiana Kidney Update, LLC</name>
      <address>
        <city>New Iberia</city>
        <state>Louisiana</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Roderick Clark</last_name>
      <phone>+001(337)233-1542</phone>
      <email>hdltweights201@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Meridian Clinical Research</name>
      <address>
        <city>Norfolk</city>
        <state>Nebraska</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Charles Harper</last_name>
      <phone>+001(402)371-0797</phone>
      <email>charper@mcrmed.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>DaVita Clinical Research</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Mark Vishnepolsky</last_name>
      <phone>+001(614)330-6674</phone>
      <email>mvishnepolsky@ksosn.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nevada Kidney Disease and Hypertension Centers, PLLC</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Samuel Kantor</last_name>
      <phone>+001(702)851-7766</phone>
      <email>SKantor@nkdhc.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>New Jersey Kidney Care, LLC</name>
      <address>
        <city>Jersey City</city>
        <state>New Jersey</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Narender Goel</last_name>
      <phone>+001(972)408-5811</phone>
      <email>Narender.Goel@fmc-na.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Brookview Hills Research Associates LLC</name>
      <address>
        <city>Winston-Salem</city>
        <state>North Carolina</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Gregory Greenwood</last_name>
      <phone>+001(877)330-2919</phone>
      <email>greenwood.gregory@yahoo.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Knoxville Kidney Center PLLC</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kendra Hendon</last_name>
      <phone>+001(865)692-3462</phone>
      <email>kendra_hendon@hotmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Davita Clinical Research</name>
      <address>
        <city>El Paso</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jaime Gonzalez</last_name>
      <phone>+001(915)781-7849</phone>
      <email>drgonzalez@elpasokidneyspecialists.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Texas Institute for Kidney and Endocrine Disorders</name>
      <address>
        <city>Lufkin</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lance Sloan</last_name>
      <phone>+001(936)414-3636</phone>
      <email>tikedlufkin@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Clinical Advancement Center, PLLC</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Pablo Pergola</last_name>
      <phone>+001(210)223-4444</phone>
      <email>ppergola@raparesearch.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kidney Specialists of North Houston, PLLC</name>
      <address>
        <city>Shenandoah</city>
        <state>Texas</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Frome</last_name>
      <phone>+001(936)273-0836</phone>
      <email>afrome18@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Southern Utah Kidney and Hypertension Center</name>
      <address>
        <city>Saint George</city>
        <state>Utah</state>
        <zip>00000</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carlos Leon-Forero</last_name>
      <phone>+001(435)652-1135</phone>
      <email>carlitoleone@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEDIC - Centro de Investigacion Clinica</name>
      <address>
        <city>Caba</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Gelersztein</last_name>
      <phone>+54114826-1208</phone>
      <email>elizabeth.g@cedic-argentina.com.ar</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigaciones Médicas</name>
      <address>
        <city>Mar del Plata</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Andrés Alvarisqueta</last_name>
      <phone>+542234917628</phone>
      <email>andres.alvarisqueta@cimmdp.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Instituto Médico Catamarca - IMEC</name>
      <address>
        <city>Rosario</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Natacha Maldonado</last_name>
      <phone>+543412985581</phone>
      <email>natachamaldonado@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CEREHA S.A.- Centro de Estudios Renales e Hipertensión Art</name>
      <address>
        <city>Sarandi</city>
        <country>Argentina</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Alicia Elbert</last_name>
      <phone>+54114217-0963</phone>
      <email>alicia.elbert.nd@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Renal Research, Gosford</name>
      <address>
        <city>Gosford</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Simon Roger</last_name>
      <phone>+61243237977</phone>
      <email>simon@renalresearch.com.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nepean Hospital</name>
      <address>
        <city>Kingswood</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Muralikrishna Komala</last_name>
      <phone>+61247344355</phone>
      <email>Muralikrishna.Gangadharankomala@health.nsw.gov.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Macquarie University</name>
      <address>
        <city>Macquarie Park</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Bernard Champion</last_name>
      <phone>+61298122976</phone>
      <email>bernard.champion@mq.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal North Shore Hospital</name>
      <address>
        <city>St Leonards</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Carol Pollock</last_name>
      <phone>+610299264652</phone>
      <email>carol.pollock@sydney.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Westmead Hospital</name>
      <address>
        <city>Westmead</city>
        <state>New South Wales</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Vincent Lee</last_name>
      <phone>+61288906962</phone>
      <email>vincent_lee@wmi.usyd.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Austin Health</name>
      <address>
        <city>Heidelberg</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elif Ekinci</last_name>
      <phone>61394962250</phone>
      <email>elif.ekinci@unimelb.edu.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Royal Melbourne Hospital</name>
      <address>
        <city>Parkville</city>
        <state>Victoria</state>
        <country>Australia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jean Tan</last_name>
      <phone>+61393427053</phone>
      <email>Jean.Tan@mh.org.au</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CARe Clinic</name>
      <address>
        <city>Red Deer</city>
        <state>Alberta</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josias Badenhorst</last_name>
      <phone>589-815-0803</phone>
      <email>josias@careclinicrd.ca</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Albion Finch Medical Centre</name>
      <address>
        <city>Toronto</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Anil Gupta</last_name>
      <phone>416-741-1500</phone>
      <email>drgupta106@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Fadia El Boreky Medicine Professional</name>
      <address>
        <city>Waterloo</city>
        <state>Ontario</state>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Fadia El Boreky</last_name>
      <phone>519-569-7592</phone>
      <email>fadiaboreky@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University First Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Minghui Zhao</last_name>
      <phone>13501243815</phone>
      <email>Zhaomh20212021@163.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Peking University Third Hospital</name>
      <address>
        <city>Beijing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Lian He</last_name>
      <phone>13391760656</phone>
      <email>ducklianhe@126.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Second Affiliated Hospital Chongqing Medical University</name>
      <address>
        <city>Chongqing</city>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Xiaohui Liao</last_name>
      <phone>13594350439</phone>
      <email>1263201771@qq.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Aarhus University Hospital</name>
      <address>
        <city>Aarhus N</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Johan Povlsen</last_name>
      <phone>+4578450000</phone>
      <email>johan.povlsen@skejby.rm.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Herlev and Gentofte Hospital</name>
      <address>
        <city>Herlev</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ditte Hansen</last_name>
      <phone>+4538682056</phone>
      <email>ditte.hansen.04@regionh.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Holbæk Sygehus</name>
      <address>
        <city>Holbæk</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Morten Lindhardt</last_name>
      <phone>+4551922907</phone>
      <email>moli@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Sjællands Universitetshospital</name>
      <address>
        <city>Roskilde</city>
        <country>Denmark</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rikke Borg</last_name>
      <phone>+4593566535</phone>
      <email>rbor@regionsjaelland.dk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Klinikum Region Hannover GmbH</name>
      <address>
        <city>Hannover</city>
        <country>Germany</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Jakob Menne</last_name>
      <phone>+49(511)9272400</phone>
      <email>jan.menne@krh.de</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Prince of Wales Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cheuk Chun SZETO</last_name>
      <phone>(852)35053101</phone>
      <email>cheukchunszeto@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Queen Mary Hospital</name>
      <address>
        <city>Hong Kong</city>
        <country>Hong Kong</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Chi Wai TANG</last_name>
      <phone>(852)22553603</phone>
      <email>scwtang@hku.hk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Chubu Rosai Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yoshiro Fujita</last_name>
      <phone>+81526525511</phone>
      <email>Yoshiro.F.M.D@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Daido Hospital</name>
      <address>
        <city>Aichi, Nagoya</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hideaki Shimizu</last_name>
      <phone>+81526116261</phone>
      <email>daido_shimizu1@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Juntendo University Urayasu Hospital</name>
      <address>
        <city>Chiba, Urayasu</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hitoshi Suzuki</last_name>
      <phone>+81473533111</phone>
      <email>shitoshi@juntendo.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kurume University Hospital</name>
      <address>
        <city>Fukuoka, Kurume</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kei Fukami</last_name>
      <phone>+81942353311</phone>
      <email>fukami@med.kurume-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nakayamadera Imai Clinic</name>
      <address>
        <city>Hyogo, Takarazuka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enyu Imai</last_name>
      <phone>+81797862600</phone>
      <email>ADS12069@nifty.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Takai Naika Clinic</name>
      <address>
        <city>Kanagawa, Kamakura</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masahiko Takai</last_name>
      <phone>+81467435556</phone>
      <email>chiken5556@yahoo.co.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Shinshu University Hospital</name>
      <address>
        <city>Nagano, Matsumoto</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Yuji Kamijo</last_name>
      <phone>+81263354600</phone>
      <email>yujibeat@shinshu-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Kawasaki Medical School Hospital</name>
      <address>
        <city>Okayama, Kurashiki</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hajime Nagasu</last_name>
      <phone>+8186462-1111</phone>
      <email>HajimeNagasu@kms-ndh.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Osaka General Medical Center</name>
      <address>
        <city>Osaka, Osaka</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Terumasa Hayashi</last_name>
      <phone>+81666921201</phone>
      <email>t-hayashi@abelia.ocn.ne.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Saitama Medical University Hospital</name>
      <address>
        <city>Saitama, Iruma-gun</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hirokazu Okada</last_name>
      <phone>+81492761111</phone>
      <email>hirookda@saitama-med.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>The University of Tokyo Hospital</name>
      <address>
        <city>Tokyo, Bunkyo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hiroshi Nishi</last_name>
      <phone>+81338155411</phone>
      <email>hrnishi-tky@g.ecc.u-tokyo.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Tokyo-Eki Center-building Clinic</name>
      <address>
        <city>Tokyo, Chuo-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Arihiro Kiyosue</last_name>
      <phone>+81335176688</phone>
      <email>arihiro.kiyosue@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Nihon University Itabashi Hospital</name>
      <address>
        <city>Tokyo, Itabashi-ku</city>
        <country>Japan</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Masanori Abe</last_name>
      <phone>+81339728111</phone>
      <email>abe.masanori@nihon-u.ac.jp</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Kebangsaan Malaysia</name>
      <address>
        <city>Cheras, Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Abdul Halim Abdul Gafor</last_name>
      <phone>603-91702108</phone>
      <email>halimgafor@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University of Malaya Medical Centre</name>
      <address>
        <city>Kuala Lumpur</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Soo Kun Lim</last_name>
      <email>limsk@ummc.edu.my</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Selayang</name>
      <address>
        <city>Selangor</city>
        <country>Malaysia</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Hin Seng Wong</last_name>
      <phone>0060361263333</phone>
      <email>hinseng@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Centro de Investigacion Cardiometabolica de Aguascalientes</name>
      <address>
        <city>Aguascalientes</city>
        <country>Mexico</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Enrique Morales Villegas</last_name>
      <phone>524499782545</phone>
      <email>drmorvi@prodigy.net.mx</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Dunedin Hospital</name>
      <address>
        <city>Dunedin</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Rob Walker</last_name>
      <phone>+6434740999</phone>
      <email>rob.walker@otago.ac.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research Kapiti</name>
      <address>
        <city>Paraparaumu</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Nicola Pointing</last_name>
      <phone>6449081001</phone>
      <email>NicolaP@p3research.co.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>P3 Research</name>
      <address>
        <city>Tauranga</city>
        <country>New Zealand</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Kingsley Nirmalaraj</last_name>
      <phone>+6475790453</phone>
      <email>Kingsley.Nirmalaraj@bopdhb.govt.nz</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>IndividualProfessional Medical Practice</name>
      <address>
        <city>Gdansk</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Adam Grzybowski</last_name>
      <phone>+48585357196,+48607442725</phone>
      <email>agrzybowski@uck.gda.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Medicome Limited Liability Company</name>
      <address>
        <city>Oswiecim</city>
        <country>Poland</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Iwona Kobielusz-Gembala</last_name>
      <phone>+48604517177</phone>
      <email>iwonagembala@wp.pl</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Moscow 1st State Med.Univ.n.a.I.M.Sechenov</name>
      <address>
        <city>Moscow</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Sergey Moiseev</last_name>
      <phone>+74992485736</phone>
      <email>avt420034@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>St. Petersburg GUZ City Hospital no. 31, St. Petersburg</name>
      <address>
        <city>St. Petersburg</city>
        <country>Russian Federation</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Ashot Essaian</last_name>
      <phone>+8921-931-22-53</phone>
      <email>essaian.ashot@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Vall d'Hebron</name>
      <address>
        <city>Barcelona</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>María José Soler</last_name>
      <phone>+34934893000ext.4872</phone>
      <email>m.soler@vhebron.net</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital de Bellvitge</name>
      <address>
        <city>L'Hospitalet de Llobregat</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Josep Cruzado</last_name>
      <phone>+34932607604</phone>
      <email>jmcruzado@bellvitgehospital.cat</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Clínico de Valencia</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jose Luis Gorriz Teruel</last_name>
      <phone>+34961973811</phone>
      <email>jlgorriz@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Hospital Dr. Peset</name>
      <address>
        <city>Valencia</city>
        <country>Spain</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Veronica Escudero Quesada</last_name>
      <phone>+34961622456</phone>
      <email>veesque@gmail.com</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>CTC Sahlgrenska Universitetssjukhuset</name>
      <address>
        <city>Göteborg</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dan Curiac</last_name>
      <phone>+46313429670</phone>
      <email>dan.curiac@vgregion.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>ProbarE i Stockholm</name>
      <address>
        <city>Stockholm</city>
        <country>Sweden</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Peter Bosson</last_name>
      <phone>+46(0)723942294</phone>
      <email>peter.bosson@probare.se</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>University Hospital Coventry</name>
      <address>
        <city>Coventry</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Harpal Randeva</last_name>
      <phone>02476964000</phone>
      <email>harpal.randeva@uhcw.nhs.uk</email>
    </contact>
  </location>
  <location>
    <facility>
      <name>Barts and The London School of Medicine and Dentistry</name>
      <address>
        <city>London</city>
        <country>United Kingdom</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Manish Saxena</last_name>
      <phone>+442078825657</phone>
      <email>m.saxena@qmul.ac.uk</email>
    </contact>
  </location>
  <location_countries>
    <country>Argentina</country>
    <country>Australia</country>
    <country>Canada</country>
    <country>China</country>
    <country>Denmark</country>
    <country>Germany</country>
    <country>Hong Kong</country>
    <country>Japan</country>
    <country>Malaysia</country>
    <country>Mexico</country>
    <country>New Zealand</country>
    <country>Poland</country>
    <country>Russian Federation</country>
    <country>Spain</country>
    <country>Sweden</country>
    <country>United Kingdom</country>
    <country>United States</country>
  </location_countries>
  <link>
    <url>https://www.mystudywindow.com</url>
    <description>Related Info</description>
  </link>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>February 1, 2021</study_first_submitted>
  <study_first_submitted_qc>February 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">February 3, 2021</study_first_posted>
  <last_update_submitted>November 17, 2021</last_update_submitted>
  <last_update_submitted_qc>November 17, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 18, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Kidney Diseases</mesh_term>
    <mesh_term>Renal Insufficiency, Chronic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Yes</sharing_ipd>
    <ipd_description>After the study is completed and the primary manuscript is accepted for publishing, researchers can use this following link https://www.mystudywindow.com/msw/datasharing to request access to the clinical study documents regarding this study, and upon a signed &quot;Document Sharing Agreement&quot;. Also, Researchers can use the following link https://www.mystudywindow.com/msw/datasharing to find information in order to request access to the clinical study data, for this and other listed studies, after the submission of a research proposal and according to the terms outlined in the website.&#xD;
The data shared are the raw clinical study data sets.</ipd_description>
    <ipd_info_type>Study Protocol</ipd_info_type>
    <ipd_info_type>Statistical Analysis Plan (SAP)</ipd_info_type>
    <ipd_info_type>Clinical Study Report (CSR)</ipd_info_type>
    <ipd_time_frame>After all regulatory activities are completed in the US and EU for the product and indication, and after the primary manuscript has been accepted for publication.</ipd_time_frame>
    <ipd_access_criteria>For study documents - upon signing of a 'Document Sharing Agreement'. For study data - 1. after the submission and approval of the research proposal (checks will be performed by both the independent review panel and the sponsor, including checking that the planned analysis does not compete with sponsor's publication plan); 2. and upon signing of a 'Data Sharing Agreement'.</ipd_access_criteria>
    <ipd_url>https://www.mystudywindow.com/msw/datasharing</ipd_url>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

